Abstract
Background: Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach.
Objective: This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation.
Method: We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs.
Results: We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects.
Conclusion: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.
Keywords: Liver transplant, liposomes, drug delivery, ischaemia-reperfusion injury, RNA interference, small interference RNA.
Current Pharmaceutical Design
Title:Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury
Volume: 24 Issue: 23
Author(s): H. Susana Marinho, Paulo Marcelino, Helena Soares and Maria Luísa Corvo*
Affiliation:
- Instituto de Investigacao do Medicamento (iMed.ULisboa), Faculdade de Farmacia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa,Portugal
Keywords: Liver transplant, liposomes, drug delivery, ischaemia-reperfusion injury, RNA interference, small interference RNA.
Abstract: Background: Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach.
Objective: This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation.
Method: We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs.
Results: We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects.
Conclusion: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.
Export Options
About this article
Cite this article as:
Marinho Susana H. , Marcelino Paulo , Soares Helena and Corvo Luísa Maria*, Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury, Current Pharmaceutical Design 2018; 24 (23) . https://dx.doi.org/10.2174/1381612824666180807124356
DOI https://dx.doi.org/10.2174/1381612824666180807124356 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Role of Mitochondria on Muscle Cell Death and Meat Tenderization
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Meet Our Editorial Board Member
Current Gene Therapy Ocular Vascular Involvement in the Rheumatic Diseases
Current Rheumatology Reviews Penile Rehabilitation After Radical Prostatectomy
Current Drug Targets Heat Shock Proteins and Proteasome Function in Neurodegeneration
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology Synthesis and Evaluation of 1-hydroxybenzotriazole Derivatives: Dual Inhibitors of Carbonic Anhydrase II and Sodium Hydrogen Exchanger I
Letters in Organic Chemistry The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Molecular Imaging of Vascular Thrombosis
Current Molecular Imaging (Discontinued) IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.
Current Clinical Pharmacology Drug Metabolism and Pharmacokinetics of Dammarane Triterpenoids
Current Drug Metabolism Calreticulin in the Heart: From Embryological Development to Cardiac Pathology.
Current Molecular Medicine Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Ligands: Novel Pharmacological Agents in the Treatment of Ischemia Reperfusion Injury
Current Molecular Medicine Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology A Review on the Most Important Medicinal Plants Effective in Cardiac Ischemia-Reperfusion Injury
Current Pharmaceutical Design Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Melatonin having Therapeutic Bone Regenerating Capacity in Biomaterials
Current Pharmaceutical Biotechnology